As a result, BRCA1/2 knockdown dramatically increased sensitivity to cisplatin in KYSE410 and ZEC-014-1 cells (Fig. 4d, Supplementary Fig. 9b, c), indicating a potential novel therapeutic strategy to ESCC patients with BRCA1/2 mutations. Here, BRCA1 is linked to esophageal squamous cell carcinoma.